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Vaccines that protect against infection with the types of human papillomavirus (HPV) commonly associated with cervical cancer
(HPV 16 and 18) and genital warts (HPV 6 and 11) are expected to become available in the near future. Because HPV vaccines are
prophylactic, they must be administered prior to exposure to the virus, ideally during preadolescence or adolescence. The young
age of the target vaccination population means that physicians, parents, and patients will all be involved in the decision-making
process. Research has shown that parents and patients are more likely to accept a vaccine if it is eﬃcacious, safe, reasonably priced,
and recommended by a physician. Widespread education of physicians, patients, and parents about the risks and consequences of
HPV infection and the beneﬁts of vaccination will be instrumental for fostering vaccine acceptance.
Copyright © 2006 Bernard Gonik. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Human papillomavirus (HPV) is the most common sexually
transmitted infection (STI) and a known risk factor for cer-
vicalcancer[1, 2]. HPV is highly prevalent in younger popu-
lations, with prevalence rates of approximately 50% in sexu-
allyactiveadolescentgirlsandyoungwomen[3].Earlyageof
ﬁrst sexual intercourse is associated with greater susceptibil-
itytoHPVinfection,possiblyduetocervicalimmaturity[4].
Currentestimatessuggestthatapproximately15%ofsexually
active adults in the United States have clinical or subclinical
infections [5]. Despite the fact that most sexually active indi-
viduals will become exposed throughout their lives, knowl-
edge about HPV and the diseases that HPV causes is gener-
ally very limited [6].
TheaverageageofﬁrstsexualintercourseinNorthAmer-
ica is approximately 16 years for both men and women [7].
To provide the greatest public health beneﬁt, HPV vaccines
must be administered prior to initiating sexual activity and
hence would be most eﬀective if oﬀered during early ado-
lescence. Because gynecologists often serve as the sole health
care provider for many women, they are in an excellent po-
sition to disseminate information about the risks and con-
sequences of HPV infection as well as provide information
about HPV vaccines that will soon become commercially
available.
GENERAL AWARENESS OF HPV
Population awareness of the risks associated with acquiring
HPV and the consequences associated with infection is low.
Numerous studies have demonstrated that most patients are
unaware of HPV and its association with genital warts and
cervical cancer [2, 6, 8–14]. Furthermore, awareness has not
improved in the past decade: approximately 33% of women
and half of men surveyed have never heard of HPV [9, 11].
Nonetheless, there is a desire for more information about
HPV [15]. Women want to know how HPV is transmitted,
including whether intercourse is required to transmit dis-
ease, and how they and their sexual partners can prevent be-
coming infected. Additional information of interest includes
whether condoms protect against the virus, how HPV is de-
tected, the likelihood of spontaneous resolution of infection,
and the risk of cervical cancer [16].
HPV VACCINE ACCEPTANCE
Vaccines designed to reduce the incidence of HPV infection
are in late stages of clinical development and studies to date
have demonstrated that these vaccines are safe and highly ef-
ﬁcacious. Widespread acceptance of HPV vaccines are likely
to lend enormous health beneﬁts by decreasing morbidity
and mortality associated with cervical cancer and by reduc-
ing the psychosocial burden of both genital warts and abnor-
mal Papanicolaou (Pap) test results. Savings in health care
expenditures, including treatments for genital warts, prein-
vasivecervicallesions,andcervicalcancerwouldalsobecon-
siderable [17].
Historically, however, vaccine availability has not always
translated to widespread use. Underestimates of both the
level of risk and the severity of HPV-associated disease may2 Infectious Diseases in Obstetrics and Gynecology
become barriers to vaccine acceptance [18]. Hence, physi-
cian, parent, and patient education about HPV and HPV
vaccines will be crucial to eﬀectively implement HPV vac-
cination programs.
Vaccineacceptabilityamongindividuals
Attitudes regarding HPV vaccine acceptance can be assessed
based on acceptability of previous vaccines and through
questionnaires completed by patients, parents, and health
care providers. For example, Kahn et al presented question-
naires to 52 young women regarding HPV vaccination, and
found that most viewed vaccination positively [19]. Fur-
thermore, most reported a high intention of receiving the
vaccine, both for themselves and their hypothetical daugh-
ters. Knowledge about HPV and the vaccine, personal beliefs
aboutvaccination,beliefsthatotherswouldapproveofvacci-
nation,highernumberofsexualpartners,andperceivedsup-
port of provider, partner, and parents were all signiﬁcantly
associated with intention to receive the vaccine [19]. In a
separate study of 256 college students, 74% endorsed HPV
vaccination [20]. Of those surveyed, acceptance signiﬁcantly
correlated with higher number of sexual partners, parental
support, endorsement of universal HPV vaccination, low
cost, and vaccine safety. Hoover et al evaluated knowledge
of HPV and attitudes toward HPV vaccination and clinical
trial participation among 60 female adolescents and young
adults [21]. Almost all of the participants expressed interest
in receiving a vaccine that would prevent cervical cancer and
genital warts. Another study examined the attitudes about
hypothetical HPV vaccines in adolescent (n = 20) and adult
women (n = 20) attending two urban STI clinics [22]. Here,
the idea of an HPV vaccine was favorably received and sev-
eral factors aﬀected potential acceptance, including vaccine
eﬃcacy, physician endorsement, and cost.
Vaccineacceptabilityamongparents
Vaccine acceptance among parents is not universal. Al-
though, in general, overall conﬁdence in vaccines remains
high, many Americans distrust public health policy and
refuse vaccination on these grounds [23]. Concern over po-
tential side-eﬀects from vaccines is a common barrier to vac-
cination [24]. Parents may also object to vaccination for reli-
gious or philosophical reasons [25].
Toovercomethesebarriers,cliniciansshouldinformpar-
entsoftheprevalenceofHPVamongadolescentsanddiscuss
the potential consequences of forgoing vaccination and be-
coming infected. Although many childhood vaccines are for
diseases that are now rare, HPV is highly prevalent and ed-
ucational eﬀorts should stress that most sexually active ado-
lescents will acquire HPV.
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unique barriers to parental consent not previously encoun-
tered with other vaccines. Parents may feel that consenting
to a vaccine for an STI may inadvertently encourage their
adolescent children to engage in sexual intercourse. Simi-
larly,parentsmayfeelthatvaccinationatanearlyagewillen-
courage earlier sexual debut [26]. Acceptance of the vaccine
represents an acknowledgment of risk of infection [27], and
some parents may have diﬃculty accepting the fact that their
children are approaching an age at which sexual activity is
often initiated.
Contrary to these beliefs, several studies have suggested
that the sexually transmitted nature of HPV may not pose a
majorobstacletoHPVvaccineacceptance.Inonestudy,70%
of parents approved of vaccination for STIs [18, 28]. Desire
to protect their children, concern about speciﬁc disease char-
acteristics, and personal experience with an STI were directly
correlated with vaccine acceptance. Rejection was associated
with the perception that their child was at low risk for in-
fection or with the parent having a low concern about sever-
ity of the disease. In a similar study, Zimet et al questioned
278 parents about their attitudes toward adolescent vacci-
nation, incorporating nine hypothetical STI scenarios de-
ﬁned along four diﬀerent dimensions: mode of transmission
(STIvsnon-STI),severity(curable/chronic/fatal),vaccineef-
ﬁcacy (50%,70%,90%), and behavioral method for preven-
tion (available/not available) [27]. Interestingly, whether a
disease was sexually transmitted did not aﬀect the parents’
decision. Instead, severity of the hypothetical disease and
vaccine eﬃcacy predicted vaccine acceptance [27].
When parents who were undecided about HPV vacci-
nation were provided with a basic information sheet about
HPV and HPV vaccines, they became signiﬁcantly more
likely to support HPV vaccination [26]. Physician endorse-
ment and school requirements have also been identiﬁed
as important catalysts for parental vaccine acceptance [29].
Conversely, information acquired from friends, relatives, or
advertisements had a marginal impact.
Vaccineacceptabilityamonghealth
careprofessionals
Endorsement by professional organizations is a major pre-
dictor of HPV vaccine acceptance. One study concluded that
a recommendation from the American College of Obstetri-
cians and Gynecologists would be the most important factor
inﬂuencing whether gynecologists would recommend vacci-
nation [29]. If the endorsements included a speciﬁc age for
vaccination, this would undoubtedly increase acceptance of
early-adolescent HPV vaccination.
Educational initiatives targeting health care profession-
als have demonstrated eﬀectiveness in fostering vaccine ac-
ceptance. A study to measure the eﬀectiveness of a statewide
peer educational program on changes in clinician immu-
nization practice patterns and behaviors was conducted be-
tween June 1999 and October 2000 (Figure 1)[ 30]. Inter-
ventions included hospital grand rounds lectures and oﬃce-
based small group in-service sessions. Forty-two percent of
the 532 providers who attended the 16 grand rounds lec-
tures completed both the pre- and posttests; the response
rate was the same for the 368 physicians who attended the
15 oﬃce-based sessions. Knowledge (P<. 05) and practice
attitudes (P<. 01) pertaining to vaccine-preventable dis-
ease and immunization improved after attending a lecture
or in-service session. Grand rounds were more eﬀective than
in-service sessions at convincing physicians to change theirBernard Gonik 3
Give patients
vaccine
information
Have vaccines
in their oﬃce
Include an adult
immunization
form
Review patient
status at least
annually
0
20
40
60
80
100
Did not participate (n = 39)
In-service only (n = 19)
Grand rounds only (n = 47)
Both grand rounds and in-service (n = 49)
Figure 1: Interventions, participation, and oﬃce practice. Gyne-
cologists who attended in-service or grand rounds educational lec-
tures were more likely to vaccinate or provide vaccine information
to their patients than those who did not [30].
vaccine-preventable disease oﬃce practices (P<. 01), but ev-
eryone who participated in one or more interventions had
better knowledge recall, improved attitudes toward vaccine-
preventable disease, and practice patterns that were more
likely to improve patient vaccine awareness compared with
those who did not participate (P<. 05). Thus, educational
interventions can positively inﬂuence immunization-related
practice patterns.
Educational eﬀorts aimed at health care professionals
should include physician assistants and nurse practitioners,
as well as physicians. Educating patients about HPV and
the HPV vaccine will be time consuming, and the assistance
these groups can provide will prove to be invaluable.
Clinicians should provide information in an individual-
ized fashion, tailoring educational sessions according to the
patient’s background, age, and literacy level [16]. An eﬀort
should be made to provide needed information to parents
and adolescents without creating needless anxiety over the
situation [31]. Nonetheless, it is crucial that the high risk of
infection,thefrequentnegativeconsequencesassociatedwith
infection, and the importance of vaccinating in early adoles-
cence, before the individual has become sexually active, be
made clear to the parent.
CONCLUSIONS
Prophylactic HPV vaccines may soon become available for
public distribution; however, general knowledge about HPV
and HPV-associated disease is limited and may aﬀect vaccine
acceptability. Research suggests that vaccine acceptance will
be maximized by eﬀectively communicating the risks associ-
ated with HPV infection and the beneﬁts of vaccination. Ed-
ucational initiatives targeted towards patients, parents, and
health care providers will play key roles in fostering positive
attitudes towards vaccination.
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